Tau immunotherapies have now advanced from proof-of-concept studies to Phase II clinical trials. This review briefly outlines developments in the field and discusses how these therapies may work, which involves multiple variables that are connected in complex ways. These various factors are likely to define therapeutic success in humans and have not been thoroughly investigated, at least based on published reports.
BoutajangoutA, QuartermainD, SigurdssonEM. (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 30, 16559–16566.
5.
BoutajangoutA, IngadottirJ, DaviesP, SigurdssonEM. (2010) Passive tau immunotherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy.S. Alzheimers Dement. 6, 578.
6.
BoutajangoutA, IngadottirJ, DaviesP, SigurdssonEM. (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 118, 658–667.
7.
KrishnamurthyPK, DengY, SigurdssonEM. (2011) Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry. 2, 59–65.
8.
CongdonEE, GuJ, SaitHB, SigurdssonEM. (2013) Antibody uptake into neurons occurs primarily via clathrin-dependent Fcgamma receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem. 288, 35452–35465.
9.
GuJ, CongdonEE, SigurdssonEM. (2013) Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. J Biol Chem. 288, 33081–33095.
10.
LinY, GuJ, RajamohamedsaitHB, RajamohamedsaitWJ, SigurdssonEM. (2014) Monitoring tau pathology and monoclonal antibodies in vivo with two-photon imaging.P. Alzheimers Dement. 10, 789.
11.
KrishnaswamyS, LinY, RajamohamedsaitWJ, RajamohamedsaitHB, KrishnamurthyP, SigurdssonEM. (2014) Antibody-derived in vivo imaging of tau pathology. J Neurosci. 34, 16835–16850.
12.
CongdonEE, LinY, RajamohamedsaitHB, ShamirDB, KrishnaswamyS, RajamohamedsaitWJ, RasoolS, GonzalezV, LevengaJ, GuJ, HoefferC, SigurdssonEM. (2016) Affinity of tau antibodies for solubilized pathological tau species but not their immunogen or insoluble tau aggregates predicts in vivo and ex vivo efficacy. Mol Neurodegener. 11, 62–85.
13.
KrishnaswamyS, LinY, WuQ, SigurdssonEM. (2018) Near infrared non-invasive imaging of tau aggregates in mouse models. In Sigurdsson EM, Calero M, Gasset M, Eds. Springer - in press. Amyloid Proteins: Methods and Protocols. New York: Humana Press.
14.
ShamirDB, RosenqvistN, RasoolS, PedersenJT, SigurdssonEM. (2016) Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach. Alzheimers Dement. 12, 1098–1107.
15.
RajamohamedsaitHB, RasoolS, LinY, SigurdssonEM. (2017) Immunization with a phospho-tau peptide reduces both tau and Aβ pathology in 3xTg mice. Sci Rep. 7, 17034.
16.
ShamirD, DengY, SigurdssonEM. (2018) Live imaging of the interaction between pathological tau protein and antibodies in a human neuron-like culture model. In Sigurdsson EM, Calero M, Gasset M, Eds. Springer - in press. Amyloid Proteins: Methods and Protocols. New YorkHumana Press.
17.
ShamirDB, DengY, SigurdssonEM. (2017) Live time-lapse imaging in a human neuron-like model to clarify the mechanisms of intracellular antibody-mediated neutralization/clearance of Alzheimer’s brain derived tau protein.638.06. Soc Neurosci Abstr. Washington, DC.
18.
WuQ, LinY, GuJ, SigurdssonEM. (2017) Dynamic characterization of brain uptake of tau antibodies, their entry into neurons and efficacy in clearing tau aggregates in live animals by two-photon imaging.454. Soc Neurosci Abstr07.
19.
CongdonEE, ChukwuJ, UjlaD, ShamirD, SaitHBR, KongX, SigurdssonEM. (2017) Partial humanization alters antibody charge and impairs primarily intracellular- but to some extent extracellular efficacy in targeting pathological tau protein.478. Soc Neurosci Abstr20.
20.
ChaiX, WuS, MurrayTK, KinleyR, CellaCV, SimsH, BucknerN, HanmerJ, DaviesP, O’NeillMJ, HuttonML, CitronM. (2011) Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression. J Biol Chem. 286, 34457–34467.
21.
BiM, IttnerA, KeYD, GotzJ, IttnerLM. (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 6, e26860.
22.
TheunisC, Crespo-BielN, GafnerV, PihlgrenM, Lopez-DeberMP, ReisP, HickmanDT, AdolfssonO, ChuardN, NdaoDM, BorghgraefP, DevijverH, vanLF, PfeiferA, MuhsA. (2013) Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 8, e72301.
23.
IttnerA, BertzJ, SuhLS, StevensCH, GotzJ, IttnerLM. (2015) Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice. J Neurochem. 132, 135–145.
24.
UmedaT, EguchiH, KunoriY, MatsumotoY, TaniguchiT, MoriH, TomiyamaT. (2015) Passive immunotherapy of tauopathy targeting pSer413-tau: A pilot study in mice. Ann Clin Transl Neurol. 2, 241–255.
25.
SankaranarayananS, BartenDM, VanaL, DevidzeN, YangL, CadelinaG, HoqueN, DeCarrL, KeenanS, LinA, CaoY, SnyderB, ZhangB, NitlaM, HirschfeldG, BarrezuetaN, PolsonC, WesP, RanganVS, CacaceA, AlbrightCF, MeredithJr J, TrojanowskiJQ, LeeVM, BrundenKR, AhlijanianM. (2015) Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One. 10, e0125614.
26.
LiuW, ZhaoL, BlackmanB, ParmarM, WongMY, WooT, YuF, SondhiD, KaminskySM, CrystalRG, PaulSM. (2016) Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. J Neurosci. 36, 12425–12435.
27.
NobuharaCK, DeVosSL, ComminsC, WegmannS, MooreBD, RoeAD, CostantinoI, FroschMP, PitstickR, CarlsonGA, HockC, NitschRM, MontrasioF, GrimmJ, CheungAE, DunahAW, WittmannM, BussiereT, WeinrebPH, HymanBT, TakedaS. (2017) Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro. Am J Pathol. 187, 1399–1412.
28.
BoimelM, GrigoriadisN, LourbopoulosA, HaberE, AbramskyO, RosenmannH. (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 224, 472–485.
29.
TroquierL, CaillierezM, BurnoufS, Fernandez-GomezFJ, GrosjeanMJ, ZommerN, SergeantN, Schraen-MaschkeS, BlumD, BueeL. (2012) Targeting phospho-Ser422 by active Tau immunotherapy in the THY-Tau22 mouse model: A suitable therapeutic approach. Curr Alzheimer Res. 9, 397–405.
30.
KfouryN, HolmesBB, JiangH, HoltzmanDM, DiamondMI. (2012) Trans-cellular propagation of tau aggregation by fibrillar species. J Biol Chem. 287, 19440–19451.
31.
d’AbramoC, AckerCM, JimenezHT, DaviesP. (2013) Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity. PLoS One. 8e62402.
32.
YanamandraK, KfouryN, JiangH, MahanTE, MaS, MaloneySE, WozniakDF, DiamondMI, HoltzmanDM. (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 80, 402–414.
33.
Castillo-CarranzaDL, GersonJE, SenguptaU, Guerrero-MunozMJ, Lasagna-ReevesCA, KayedR. (2014) Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.}(Suppl 1), S97-S. J Alzheimers Dis. 40, 111.
WallsKC, AgerRR, VasilevkoV, ChengD, MedeirosR, LaFerlaFM. (2014) p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci Lett. 575, 96–100.
36.
KontsekovaE, ZilkaN, KovacechB, NovakP, NovakM. (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther. 6, 44.
37.
SelenicaML, DavtyanH, HousleySB, BlairLJ, GilliesA, NordhuesBA, ZhangB, LiuJ, GestwickiJE, LeeDC, GordonMN, MorganD, DickeyCA. (2014) Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation. 11, 152.
CollinL, BohrmannB, GopfertU, Oroszlan-SzovikK, OzmenL, GruningerF. (2014) Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease.}. Brain. 137, 2834–2846.
40.
KondoA, ShahpasandK, MannixR, QiuJ, MoncasterJ, ChenCH, YaoY, LinYM, DriverJA, SunY, WeiS, LuoML, AlbayramO, HuangP, RotenbergA, RyoA, GoldsteinLE, Pascual-LeoneA, McKeeAC, MeehanW, ZhouXZ, LuKP. (2015) Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. Nature. 523, 431–436.
41.
YanamandraK, JiangH, MahanTE, MaloneySE, WozniakDF, DiamondMI, HoltzmanDM. (2015) Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2, 278–288.
42.
FunkKE, MirbahaH, JiangH, HoltzmanDM, DiamondMI. (2015) Distinct therapeutic mechanisms of tau antibodies: Promoting microglial clearance versus blocking neuronal uptake. J Biol Chem. 290, 21652–21662.
43.
D’AbramoC, AckerCM, JimenezH, DaviesP. (2015) Passive immunization in JNPL3 transgenic mice using an array of phospho-tau specific antibodies. PLoS One. 10, e0135774.
44.
LuoW, LiuW, HuX, HannaM, CaravacaA, PaulSM. (2015) Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep. 5, 11161.
45.
SchroederSK, Joly-AmadoA, GordonMN, MorganD. (2016) Tau-directed immunotherapy: A promising strategy for treating Alzheimer’s disease and other tauopathies. J Neuroimmune Pharmacol. 11, 9–25.
46.
DavtyanH, ChenWW, ZagorskiK, DavisJ, PetrushinaI, KazarianK, CribbsDH, AgadjanyanMG, Blurton-JonesM, GhochikyanA. (2017) MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine. 290, 21652–21662.
47.
DaiCL, TungYC, LiuF, GongCX, IqbalK. (2017) Tau passive immunization inhibits not only tau but also Abeta pathology. Alzheimers Res Ther. 9, 1.
48.
AgadjanyanMG, ZagorskiK, PetrushinaI, DavtyanH, KazarianK, AntonenkoM, DavisJ, BonC, Blurton-JonesM, CribbsDH, GhochikyanA. (2017) Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: Characterization and therapeutic potency. Mol Neurodegener. 12, 33.
49.
SubramanianS, SavanurG, MadhavadasS. (2017) Passive immunization targeting the N-terminal region of phosphorylated tau (residues 68-71) improves spatial memory in okadaic acid induced tauopathy model rats. Biochem Biophys Res Commun. 483, 585–589.
50.
CongdonEE, SigurdssonEM. (2018) Tau therapies for Alzheimer’s disease. in press. Nat Rev Neurol.
51.
SigurdssonEM. (2016) Tau immunotherapy. Neurodegener Dis. 16, 34–38.
52.
PedersenJT, SigurdssonEM. (2015) Tau immunotherapy for Alzheimer’s disease. Trends Mol Med. 21, 394–402.
53.
CongdonEE, KrishnaswamyS, SigurdssonEM. (2014) Harnessing the immune system for treatment and detection of tau pathology.(Suppl 1), S113-S. J Alzheimers Dis. 40, 121.
54.
SigurdssonEM. (2008) Immunotherapy targeting pathological tau protein in Alzheimer’s disease and related tauopathies. J Alzheimers Dis. 15, 157–168.
WalkerLC, DiamondMI, DuffKE, HymanBT. (2013) Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 70, 304–310.
58.
HalesCM, HuWT. (2013) From frontotemporal lobar degeneration pathology to frontotemporal lobar degeneration biomarkers. Int Rev Psychiatry. 25, 210–220.
59.
OlssonB, LautnerR, AndreassonU, OhrfeltA, PorteliusE, BjerkeM, HolttaM, RosenC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH. (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol. 15, 673–684.
60.
CoughlinD, IrwinDJ. (2017) Emerging diagnostic and therapeutic strategies for tauopathies. Curr Neurol Neurosci Rep. 17, 72.
61.
BarthelemyNR, FenailleF, HirtzC, SergeantN, Schraen-MaschkeS, VialaretJ, BueeL, GabelleA, JunotC, LehmannS, BecherF. (2016) Tau protein quantification in human cerebrospinal fluid by targeted mass spectrometry at high sequence coverage provides insights into its primary structure heterogeneity.}. J Proteome Res. 15, 667–676.
62.
BarthelemyNR, GabelleA, HirtzC, FenailleF, SergeantN, Schraen-MaschkeS, VialaretJ, BueeL, JunotC, BecherF, LehmannS. (2016) Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer’s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J Alzheimers Dis. 51, 1033–1043.
63.
Taniguchi-WatanabeS, AraiT, KametaniF, NonakaT, Masuda-SuzukakeM, TarutaniA, MurayamaS, SaitoY, ArimaK, YoshidaM, AkiyamaH, RobinsonA, MannDMA, IwatsuboT, HasegawaM. (2016) Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 131, 267–280.
64.
CongdonEE, UjlaD, ShamirD, SaitHBR, SigurdssonEM. (2016) Lack of neuronal uptake of tau antibodies impairs their efficacy in preventing tau pathology and related toxicity.285. Soc Neurosci Abstr04.
65.
McEwanWA, FalconB, VaysburdM, CliftD, OblakAL, GhettiB, GoedertM, JamesLC. (2017) Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci U S A. 114, 574–579.
66.
ModakSR, SigurdssonEM. (2017) Antibodies targeting truncated Asp421 tau protein clear human Alzheimer’s tau and prevent its toxicity in primary neuronal and mixed cortical cultures.478. Soc Neurosci Abstr19.
67.
LiT, VandesquilleM, KoukouliF, DudeffantC, YoussefI, LenormandP, GanneauC, MaskosU, CzechC, GrueningerF, DuyckaertsC, DhenainM, BayS, DelatourB, LafayeP. (2016) Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 243, 1–10.
68.
International Clinical Trials Registry (2013) A study comparing the safety and effects of a new compound, ACI-35 with placebo in patients with mild to moderate Alzheimer’s disease. http://www.isrctn.com/ISRCTN13033912.
DaiCL, ChenX, KazimSF, LiuF, GongCX, Grundke-IqbalI, IqbalK. (2015) Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna). 122, 607–617.
71.
ModakSR, SolesioM, KrishnaswamyS, CongdonEE, SigurdssonEM. (2015) Antibodies targeting truncated tau protein reduce tau pathology in primary neuronal and mixed cortical cultures.579. Soc Neurosci Abstr14.
72.
LeeSH, Le PichonCE, AdolfssonO, GafnerV, PihlgrenM, LinH, SolanoyH, BrendzaR, NguH, ForemanO, ChanR, ErnstJA, DiCaraD, HotzelI, SrinivasanK, HansenDV, AtwalJ, LuY, BumbacaD, PfeiferA, WattsRJ, MuhsA, Scearce-LevieK, AyalonG. (2016) Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 16, 1690–1700.
73.
JichaGA, BowserR, KazamIG, DaviesP. (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 48, 128–132.
74.
NisbetRM, Van der JeugdA, LeinengaG, EvansHT, JanowiczPW, GotzJ. (2017) Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain. 140, 1220–1230.
75.
IsingC, GallardoG, LeynsCEG, WongCH, StewartF, KoscalLJ, RohJ, RobinsonGO, RemolinaSJ, HoltzmanDM. (2017) AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. J Exp Med. 214, 1227–1238.
76.
RosenmannH, GrigoriadisN, KarussisD, BoimelM, TouloumiO, OvadiaH, AbramskyO. (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 63, 1459–1467.
SigurdssonEM. (2016) Tau immunotherapy. In IngelssonM, LannfeltL, Eds. Springer, Immunotherapy and Biomarkers in Neurodegenerative Disorders109–120Humana Press.
79.
NovakP, SchmidtR, KontsekovaE, ZilkaN, KovacechB, SkrabanaR, Vince-KazmerovaZ, KatinaS, FialovaL, PrcinaM, ParrakV, Dal-BiancoP, BrunnerM, StaffenW, RainerM, OndrusM, RopeleS, SmisekM, SivakR, WinbladB, NovakM. (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 16, 123–134.
80.
MablyAJ, KanmertD, McDonaldJM, LiuW, CaldaroneBJ, LemereCA, O’NuallainB, KosikKS, WalshDM. (2015) Tau immunization: A cautionary tale?. Neurobiol Aging. 36, 1316–1332.
81.
KeYD, SuchowerskaAK, van der HovenJ, De SilvaDM, WuCW, vanEJ, IttnerA, IttnerLM. (2012) Lessons from tau-deficient mice. Int J Alzheimers Dis. 2012, 873270.
82.
RapoportM, DawsonHN, BinderLI, VitekMP, FerreiraA. (2002) Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 99, 6364–6369.
83.
RobersonED, Scearce-LevieK, PalopJJ, YanFR, ChengIH, WuT, GersteinH, YuGQ, MuckeL. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science. 316, 750–754.
84.
ClinicalTrials.gov. (2015) 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer’s Disease (ADAMANT). https://clinicaltrials.gov/show/NCT02579252.
85.
ClinicalTrials.gov. (2014) A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intously Administered BMS-986168 in Healthy Subjects. US National Library of Medicine, https://clinicaltrials.gov/show/NCT02294851.
86.
ClinicalTrials.gov. (2015) Multiple Ascending Dose Study of Intously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy (CN002-003). https://clinicaltrials.gov/show/NCT02460094.
87.
ClinicalTrials.gov. (2016) A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease. https://clinicaltrials.gov/show/NCT02880956.
88.
ClinicalTrials.gov. (2016) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy. https://clinicaltrials.gov/show/NCT02985879.
89.
WestT, HuY, VerghesePB, BatemanRJ, BraunsteinJB, FogelmanI, BudurK, FlorianH, MendoncaN, HoltzmanDM. (2017) Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis. 4, 236–241.
90.
ClinicalTrials.gov. (2016) A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer’s Disease. https://clinicaltrials.gov/show/NCT02820896.
91.
ClinicalTrials.gov. (2016) A Study of LY3303560 in Healthy Participants and Participants With Alzheimer’s Disease (AD).. https://clinicaltrials.gov/show/NCT02754830.
92.
ClinicalTrials.gov. (2017) A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer’s Disease. https://clinicaltrials.gov/show/NCT03019536.
93.
HayashiML, LuL, DriverD, AlvaradoA. (2016) Antibodies to tau and uses thereof. US 2016/0251420 A. US Patent Application. 1.
94.
Saint-AubertL, LemoineL, ChiotisK, LeuzyA, Rodriguez-VieitezE, NordbergA. (2017) Tau PET imaging: Present and future directions. Mol Neurodegener. 12, 19.
95.
HallB, MakE, CervenkaS, AigbirhioFI, RoweJB, O’BrienJT. (2017) In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev. 36, 50–63.
